Royalty Report: Drugs, Therapeutic, Pharmaceuticals – Collection: 26598

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Drugs
  • Therapeutic
  • Pharmaceuticals
  • Disease
  • Medical
  • Device
  • Delivery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26598

License Grant
Licensor grants
–  an exclusive right and license in the Field, with the right to grant sublicenses, under the Licensor Intellectual Property, to use, import, offer for sale, and Promote Products in the Territory;
–  an exclusive right and license in the Field, with the right to grant sublicenses, under the Licensor Intellectual Property, to sell and distribute Products in the Territory;
–  effective on the Processing Assumption Date, an exclusive right and license under the Licensor Intellectual Property, to make and have made Trospium Once Daily for use in the Field in the Territory; and
–  during the Co-promotion Period and any period of time thereafter that Licensee has Promotional Materials that were printed prior to the end of the Copromotion Period and that contain the Licensor Logo, an exclusive, even as to Licensor, right and license in the Field in the Territory, with the right to grant sublicenses, to use the Licensor Logo on the Promotional Materials.
License Property
Compound means the chemical compound known as Trospium Chloride whose specific chemical name is 3-alpha-benziloyloxynortropane-8-spiro-1 ' – pyrrolidinium chloride, also known as spiro[8-azoniabicyclo[3,2, 1 ]octane-8, 1 '-pyrrolidinium]-3- [(hydroxydiphenyl-acetyl)-oxy ]chloride((l a, 30, 5a))-(9Cl) and any related analogues, homologues, derivative and other pharmaceutically active salts.

Finished Product means Trospium Twice-Daily or Trospium OnceDaily, as applicable, in its finished, labeled and packaged form, ready for distribution in the Field in the Territory.

Trademark(s) means the SANCTURA trademarks, owned by Esprit, and all related domain names and other trademark related rights, and/or any other trademark that either Party may apply to register in the Territory if such alternate trademark is selected for use in the Promotion of a Product in the Field by the Parties under this Agreement.

Field of Use
Field means any oral formulation of a Product for any human pharmaceutical use, and any transdermal or intravesicle formulation of a Product for use in the treatment of overactive bladder and/or urinary incontinence in any form.

Sanctura® is use for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency. Sanctura, a quarternary ammonium compound, belongs to a class of anticholinergic compounds known as muscarinic receptor antagonists. These compounds relax smooth muscle tissue found in the bladder, thus decreasing bladder contractions. Overactive or unstable detrusor muscle function is believed to be the cause of OAB.

IPSCIO Record ID: 211892

License Grant
Licensor grants an exclusive right and license in the Field, with the right to grant sublicenses to Affiliates of Licensee and of Parent at the time of such grant, to practice under the Licensors Intellectual Property, solely to use, import, offer for sale, and Promote Product in the Territory;  and an exclusive, even as to Licensor, right and license in the Field, with the right to grant sublicenses to Affiliates of Licensee and of Parent at the time of such grant, to practice under the Licensors Intellectual Property, solely to sell and distribute Product in the Territory.
License Property
The licensed property relates to the chemical compound known as trospium chloride whose specific chemical name is 3-alpha-benziloyloxynortropane-8-spiro-1’-pyrrolidinium chloride, also known as spiro[8-azoniabicyclo[3,2,1]octane-8,1’-pyrrolidinium]-3-[(hydroxydiphenyl-acetyl)-oxy]chloride(1a, 3ß, 5a)-(9Cl) and any related analogues, homologues, derivative and other pharmaceutically active salts.

The Product means any pharmaceutical preparation in final form (or, where the context so indicates, the form under development) containing Compound as a primary active therapeutic ingredient, which requires a prescription from a physician or other health care professional, for use in the Territory.

The Finished Product means the oral dosage formulation of Trospium Twice-Daily described in the Specifications and packaged and labeled and in a form ready for distribution in the Territory.

Trospium chloride is used to treat overactive bladder.

Field of Use
The Field means any oral formulation of Product for any human pharmaceutical use, and any transdermal or intravesicle formulation of Product for ·use in the treatment of overactive bladder and/or urinary incontinence in any form.

IPSCIO Record ID: 245891

License Grant
Licensor grants to the German Licensee an exclusive license under the SANCTURA XR Patents and the Licensor Know-How to use, develop, import, offer for sale, sell, or have sold Product, into and throughout the Licensees Territory.
License Property
The Compound means the chemical compound known as trospium chloride.

The Product means a controlled or extended-release oral formulation of Compound for the treatment of overactive bladder and/or urinary incontinence that requires a prescription from a physician or other health care professional in the Licensees Territory, that is intended to be administered once a day, and which but for the license granted herein, cannot be manufactured, used or sold without infringing a Valid Claim which is contained in a SANCTURA XR Patent or utilizes the Intellectual Property.

Trademark means the trademark SANCTURA XRâ„¢ and any related trademark, symbol, logo trade dress and/or trade name that Licensor may adopt and register for use in the promotion of Product.

SANCTURA XR Patents include Compositions of Quaternary Ammonium Compounds containing Bioavailability Enhancers, and, Sustained Release of Positively Charged Pharmacologically Active Molecules from a matrix containing Polymers with Polarized Oxygen Atoms, and, Once Daily Dosage forms of Trospium.

Field of Use
The field of use is for overactive bladder.

SANCTURA XR® is a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.

IPSCIO Record ID: 275817

License Grant
The Parties entered into an amendment to resolve and settle between themselves certain issues that have arisen under the Agreement and to enter into certain other agreements between them, all upon the terms and subject to the conditions set forth in this Amendment.  The Parties hereto agree to the following but not limited to
– the Parties agree that Licensor has satisfied its obligation to pay the Licensor Cost Share and that Licensor has no responsibility or obligation for Product Expenses incurred by the Parties after November 28, 2004.
– the Parties agree that Licensee shall pay Sublicensing Royalties to Licensor.
– the Parties agree that Licensee shall pay Third Party Royalties to Licensor.
– Licensor agrees to pay Licensee a percent back as a contribution towards the cost of those Phase IV post-approval marketing studies.
License Property
The licensed property relates to the chemical compound known as trospium chloride whose specific chemical name is 3-alpha-benziloyloxynortropane-8-spiro-1’-pyrrolidinium chloride, also known as spiro[8-azoniabicyclo[3,2,1]octane-8,1’-pyrrolidinium]-3-[(hydroxydiphenyl-acetyl)-oxy]chloride(1a, 3ß, 5a)-(9Cl) and any related analogues, homologues, derivative and other pharmaceutically active salts. The Product means any pharmaceutical preparation in final form (or, where the context so indicates, the form under development) containing Compound as a primary active therapeutic ingredient, which requires a prescription from a physician or other health care professional, for use in the Territory. The Finished Product means the oral dosage formulation of Trospium Twice-Daily described in the Specifications and packaged and labeled and in a form ready for distribution in the Territory.
Field of Use
The Field means any oral formulation of Product for any human pharmaceutical use, and any transdermal or intravesicle formulation of Product for ·use in the treatment of overactive bladder and/or urinary incontinence in any form.

IPSCIO Record ID: 4114

License Grant
In November 1999, Indevus (Now the Licensor) entered into an agreement with the Licensee to license the exclusive rights to develop and market certain products, including Sanctura® in the United States. In November 2006, Indevus entered into a License and Supply Agreement and an amendment to its original 1999 license agreement with the Licensee. Under the amended Agreements, the Licensee has licensed the rights to sell Sanctura XR®.
License Property
The Licensor and the Licensee will share the development and commercialization costs in the countries in the Joint Territory. If either party decides not to pursue development and commercialization of Sanctura XR®  in any country in the Joint Territory, the other party has the right to independently develop and commercialize Sanctura XR® in that country.
Field of Use
SANCTURA XR® is a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.

IPSCIO Record ID: 26559

License Grant
Licensor hereby appoints and grants to Licensee, and Licensee hereby accepts from Licensor, the exclusive right and license to use, manufacture, market, sell and distribute the Products during the term of this Agreement, upon the terms and conditions contained herein.
License Property
Licensor is a medical device company that develops products for patients in the urogynecology and gynecology markets and has developed, and continues to develop, neurostimulation devices currently being, or proposed to be, marketed under the brand names and trademarks (collectively, the Trademarks) Urgent®, Urgent-PC™ and Urgent-SQ™ (collectively as now existing or hereafter improved, modified or enhanced, the Products).

The Urgent PC Neuromodulation System uses percutaneous tibial nerve stimulation (PTNS) to treat overactive bladder and associated symptoms of urinary urgency, urinary frequency and urge incontinence.

The Urgent PC neuromodulation system is a minimally invasive device designed for office-based treatment of overactive bladder symptoms of urge incontinence, urinary urgency and urinary frequency. This product uses percutaneous tibial nerve stimulation to deliver an electrical pulse that travels to the sacral nerve plexus, a control center for bladder function.

Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 27826

License Grant
Pursuant to the Development Agreement, Licensor has granted Licensee certain intellectual property licenses related to, among other things, a pharmaceutical composition known as Dapoxetine.  As permitted by the Development Agreement, Licensee has sublicensed to Alza, Corporation (Alza) certain rights to develop and market Dapoxetine in exchange for which Licensee is entitled to receive certain milestone, royalty and other payments from Alza.  The parties now desire to, among other things, (i) terminate the Development Agreement.
License Property
“Compounds” means those compounds other than Dapoxetine covered by a Valid Claim within the scope of the Licensed Patents.

Dapoxetine is acompound developed specially for the treatment of premature ejaculation (PE) in men 18–64 years old. Dapoxetine works by inhibiting the serotonin transporter, increasing serotonin's action at the post synaptic cleft, and as a consequence promoting ejaculatory delay. As a member of the selective serotonin reuptake inhibitor (SSRI) family, dapoxetine was initially created as an antidepressant.

Field of Use
Field shall mean all therapeutic indications for use in humans (i.e. specifically excluding use in animals) within the urogenital area, including primary urinary incontinence, urge, stress and mixed incontinence, urinary urgency, interstitial cystitis, neurogenic bladder, bladder sphincter dyssynergia and irritative symptoms of benign prostate hypertrophy, hypoactive sexual desire, hyperactive sexual desire, impotence, retarded ejaculation, premature ejaculation, delayed
orgasm and anorgasmia.

IPSCIO Record ID: 279333

License Grant
Licensor hereby grants to Licensee for the Term of this Agreement an exclusive (even as to Licensor) license in the Field under the Licensor Intellectual Property to develop, make, have made, use, sell, offer for sale and import Licensed Product(s) in the Territory.
License Property
Licensed Product(s) means all finished pharmaceutical oral formulations for commercial sale (or, where the context so indicates, a Formulation Candidate) that (i) contain the Compound alone as a therapeutically active ingredient or in combination with any other pharmaceutically active ingredient, and (ii) utilize Licensor Intellectual Property.

Intellectual Property means the Licensed Patents, the Licensor Know-How and the Licensor Technology.

Licensed Patents means Patents owned or controlled by Licensor or which Licensor, through license or otherwise, has or acquires rights, which are necessary or useful for the manufacture, use or sale of Licensed Product, including, but not limited to, compositions, formulations, methods of their manufacture, or methods of their use, or otherwise relate to Licensor Know-How or Licensor Technology, including (i) any of the Patents set forth hereto that contain claims that cover, or which relate to, any aspect of Licensed Product, (ii) the Development Patents and (iii) such other Patents as the Parties may agree in writing from time to time.

5,447,729 – Multilamellar drug delivery systems
5,484,608 – Sustained-release drug delivery system

Licensor Technology means  Licensor’s bioavailability enhancement and/ or controlled-release delivery, formulation, process and manufacturing technologies, including but not limited to the Licensor Lead Technology and the technologies embodied in the Licensed Patents and the Licensor Know-How.

Licensor Lead Technology means Microtrol® multi particulate technology or, as subsequently agreed between the Parties, one of the Other Licensor Technologies as may be applied to the Compound pursuant to the Development Plan.

Compound means trospium chloride, the chemical compound whose specific chemical name is 3-alpha benziloyJoxynortropane-8-spiro-1-pyrrolidinium; chloride, or any other trospium salt.

Field of Use
Trospium chloride (“trospium”) is  indicated for urinary incontinence. Trospium is currently under evaluation in a Phase III clinical study.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.